Interventional Cardiology

Innovation, Evidence, and Education to Support Your Complex Practice

COVID-19 Response

Medtronic is supporting a public health campaign — led by the American Heart Association and the American Stroke Association — urging the public to seek emergency care when they need it. See what else we're doing in the fight against COVID-19.

Visit the Resource Center
Close-up female physician with protective gear on during Covid-19

PRODUCT AND THERAPY INNOVATION

Close up image of the cusp overlap technique with TAVR within human anatomy.

CUSP Overlap Technique

Evolut™ TAVR Best Practices 

The cusp overlap technique brings precision and control to the TAVR procedure by isolating the non-coronary cusp, providing an accurate anatomical view to access and achieve the target implant depth. In combination with slow deployment starting at the supra-annular level, the valve is able to descend to its target position with minimal catheter manipulation, minimizing the risk of interaction with the conduction system.

Resolute Onyx drug-eluting stent on a blue gradient background

THE ONLY DES INDICATED FOR HBR PATIENTS WITH 1-MO DAPT LABELING

Resolute Onyx™ DES

Evidence counts when it comes to short DAPT decisions. The Onyx ONE Clear Analysis evaluated over 1,500 complex high bleeding risk (HBR) patients, which led Resolute Onyx to become the only drug-eluting stent approved for HBR patients and labeled for 1-month DAPT.1

Close-up illustration of Endurant AAA Stent Graft sac regression within human anatomy.

Addressing Sac Regression Factors 

Endurant™ AAA Stent Graft demonstrates consistent and high sac regression rates across straightforward and complex anatomies.2,3 With:

  • Accurate placement and controlled deployment3
  • Continuous seal, fixation and graft conformability3
  • Durable hemostatic barrier and resistance  against type II endoleaks4

CLINICAL EVIDENCE

5-year Reintervention Data: IN.PACT™ Admiral™ Drug-Coated Balloon (DCB)

IN.PACT Admiral drug-coated balloon is supported by 5-year data from an IDE and real-world global study.5

Evolut TAVR Hemodynamic Data

The Evolut TAV's supra-annular, self-expanding valve design delivers exceptional hemodynamics and is the only TAVR device to demonstrate hemodynamic superiority in a low risk clinical trial vs. SAVR at one year.7

Currently Enrolling Patients: SPYRAL HTN-ON MED Trial*

Designed to determine the safety and efficacy of renal denervation (RDN) in the presence of up to three standard antihypertensive medications. Learn more at clinicaltrials.gov.

IN.PACT AV DCB Trial Results published in The New England Journal of Medicine

Patients treated with IN.PACT AV DCB show reduced need for reinterventions compared to PTA.6

Onyx One Clear Analysis Results Now Published

Read the Circulation: Cardiovascular Interventions article, evaluating Resolute Onyx DES in ~1,500 highly complex HBR patients on 1-month DAPT.

Currently Enrolling Patients: SPYRAL DYSTAL STUDY*

Designed to evaluate if a targeted procedural approach in the distal main and first order branches provides similar BP reductions as those observed in the SPYRAL HTN-OFF MED Pivotal Trial. Learn more at clinicaltrials.gov.

Contact us to learn more and discuss patient eligibility requirements for SPYRAL HTN-ON MED or SPYRAL DYSTAL trials.

*CAUTION: Investigational device. Limited by federal (U.S.) law to investigational use.

EDUCATION AND TRAINING

DAPT considerations in HBR patients

Watch as subject matter experts review case studies and discuss the most recent clinical evidence, as well as decision making for the most complex HBR patients, like those studied in the Onyx ONE Month DAPT Program.

TAVR Global Grand Rounds

Access interactive global webcasts delivered by industry-leading experts on a wide range of relevant topics related to transcatheter aortic valve replacement. 

CTO Beyond the Basics Learning Plan

Earn CEU credits while learning about different elements of CTO, including pathology, risks and benefits in treating CTO lesions, and treatment progression in cardiac catheterization procedures.

CORONARY Education, Training, and Resources

Preview the latest on-demand education for physicians, fellows, cath lab staff, and hospital administrators, designed to support individual coronary programs.

Aortic Virtual Education

As your partner in the evolving healthcare landscape, we've developed various webinar series for real-time and on-demand learning with peer-to-peer discussion.

Female healthcare professional wearing scrubs and smiling at her iPad

Medtronic Academy

Visit Medtronic Academy

Connect with us    

Follow Us On Social Media

Upcoming Events

CRT21

Virtual Participation Only
Saturdays, Feb 13-April 24

ACC.21

Virtual Participation Only
May 15-17

Additional Resources

References

1

Resolute Onyx DES IFU

2

Bӧckler D, Li C, Dansey K, et al. Sac regression is associated with lower all-cause mortality after contemporary endovascular aneurysm repair — a new paradigm for success. Presented online at ESVS 34th Annual Meeting, October 6, 2020.

3

Medtronic data on file.

4

Wakefield TW, Shulkin BL, Fellows EP, Petry NA, Spaulding SA, Stanley JC. Platelet reactivity in human aortic grafts: a prospective, randomized midterm study of platelet adherence and release products in Dacron and polytetrafluoroethylene conduits. J Vasc Surg. February 1989;9(2):234-243.

5

IN.PACT Global Study 5-year Outcomes Full Clinical Cohort, Zeller, T. VIVA 2020.

6

Lookstein RA, et al. Drug-Coated Balloons for Dysfunctional Dialysis Arteriovenous Fistulas. N Engl J Med. 2020;383:733-42. DOI: 10.1056/NEJMoa1914617. Highlighted results reported at both 180 and 210 days.

7

Popma JJ, Deeb GM, Yakubov SJ, et al. Transcatheter Aortic-Valve Replacement with a Self-Expanding Valve in Low-Risk Patients. N Engl J Med. May 2, 2019;380(18):1706-1715.